 | • レポートコード：MRC23Q37875 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥420,500 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥841,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のMET阻害薬市場について調査・分析し、世界のMET阻害薬市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（C-Met生物学的阻害剤、低分子C-Met阻害剤、C-Metアンタゴニスト抗体、HGFアンタゴニスト抗体、クリングルバリアントアンタゴニスト）、用途別セグメント分析（病院薬局、小売店、その他）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Abbott Laboratories、Johnson and Johnson、Novartis International AG、Eli Lilly and Company、Pfizer Inc., Merck & Co.、Takeda Pharmaceutical Company、GlaxosmithKline plc、Amgen Inc.、Bristol Myers Squibb、Daiichi Sankyo Company, Limitedなどが含まれています。世界のMET阻害薬市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、MET阻害薬市場規模を推定する際に考慮しました。本レポートは、MET阻害薬の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、MET阻害薬に関するビジネス上の意思決定に役立てることを目的としています。 ・MET阻害薬市場の概要 - 製品の定義 - MET阻害薬のタイプ別セグメント - 世界のMET阻害薬市場規模：タイプ別分析（C-Met生物学的阻害剤、低分子C-Met阻害剤、C-Metアンタゴニスト抗体、HGFアンタゴニスト抗体、クリングルバリアントアンタゴニスト） - MET阻害薬の用途別セグメント - 世界のMET阻害薬市場規模：用途別分析（病院薬局、小売店、その他） - 世界のMET阻害薬市場規模予測（2018年-2029年） - MET阻害薬の平均価格推移（2018年-2029年） - 前提条件と制限事項 ・メーカー別競争状況 - メーカー別市場シェア - 世界の主要メーカー、業界ランキング分析 - メーカー別平均価格 - MET阻害薬市場の競争状況およびトレンド ・MET阻害薬の地域別市場規模 - 北米のMET阻害薬市場規模（2018年-2029年） - アメリカのMET阻害薬市場規模（2018年-2029年） - ヨーロッパのMET阻害薬市場規模（2018年-2029年） - アジア太平洋のMET阻害薬市場規模（2018年-2029年） - 中国のMET阻害薬市場規模（2018年-2029年） - 日本のMET阻害薬市場規模（2018年-2029年） - 韓国のMET阻害薬市場規模（2018年-2029年） - インドのMET阻害薬市場規模（2018年-2029年） - オーストラリアのMET阻害薬市場規模（2018年-2029年） - 中南米のMET阻害薬市場規模（2018年-2029年） - 中東・アフリカのMET阻害薬市場規模（2018年-2029年） ・タイプ別セグメント：C-Met生物学的阻害剤、低分子C-Met阻害剤、C-Metアンタゴニスト抗体、HGFアンタゴニスト抗体、クリングルバリアントアンタゴニスト - 世界のMET阻害薬のタイプ別販売量（2018年-2023年） - 世界のMET阻害薬のタイプ別売上（2018年-2023年） - 世界のMET阻害薬のタイプ別価格 ・用途別セグメント：病院薬局、小売店、その他 - 世界のMET阻害薬の用途別販売量（2018年-2023年） - 世界のMET阻害薬の用途別売上（2018年-2023年） - 世界のMET阻害薬の用途別価格 ・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向 Abbott Laboratories、Johnson and Johnson、Novartis International AG、Eli Lilly and Company、Pfizer Inc., Merck & Co.、Takeda Pharmaceutical Company、GlaxosmithKline plc、Amgen Inc.、Bristol Myers Squibb、Daiichi Sankyo Company, Limited ・産業チェーンと販売チャネルの分析 - MET阻害薬産業チェーン分析 - MET阻害薬の主要原材料 - MET阻害薬の販売チャネル - MET阻害薬のディストリビューター - MET阻害薬の主要顧客 ・MET阻害薬市場ダイナミクス - MET阻害薬の業界動向 - MET阻害薬市場の成長ドライバ、課題、阻害要因 ・調査成果および結論 ・調査方法とデータソース |
Highlights
The global MET Inhibitor Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for MET Inhibitor Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for MET Inhibitor Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of MET Inhibitor Drugs include Abbott Laboratories, Johnson and Johnson, Novartis International AG, Eli Lilly and Company, Pfizer Inc., Merck & Co., Takeda Pharmaceutical Company, GlaxosmithKline plc, Amgen Inc. and Bristol Myers Squibb, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for MET Inhibitor Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding MET Inhibitor Drugs.
The MET Inhibitor Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global MET Inhibitor Drugs market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the MET Inhibitor Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Abbott Laboratories
Johnson and Johnson
Novartis International AG
Eli Lilly and Company
Pfizer Inc., Merck & Co.
Takeda Pharmaceutical Company
GlaxosmithKline plc
Amgen Inc.
Bristol Myers Squibb
Daiichi Sankyo Company, Limited
Segment by Type
C-Met Biological Inhibitors
Small Molecule C-Met Inhibitors
C-Met Antagonist Antibodies
HGF Antagonist Antibodies
Kringle Variant Antagonists
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of MET Inhibitor Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of MET Inhibitor Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 MET Inhibitor Drugs Market Overview
1.1 Product Overview and Scope of MET Inhibitor Drugs
1.2 MET Inhibitor Drugs Segment by Type
1.2.1 Global MET Inhibitor Drugs Market Value Comparison by Type (2023-2029)
1.2.2 C-Met Biological Inhibitors
1.2.3 Small Molecule C-Met Inhibitors
1.2.4 C-Met Antagonist Antibodies
1.2.5 HGF Antagonist Antibodies
1.2.6 Kringle Variant Antagonists
1.3 MET Inhibitor Drugs Segment by Application
1.3.1 Global MET Inhibitor Drugs Market Value by Application: (2023-2029)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Others
1.4 Global MET Inhibitor Drugs Market Size Estimates and Forecasts
1.4.1 Global MET Inhibitor Drugs Revenue 2018-2029
1.4.2 Global MET Inhibitor Drugs Sales 2018-2029
1.4.3 Global MET Inhibitor Drugs Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 MET Inhibitor Drugs Market Competition by Manufacturers
2.1 Global MET Inhibitor Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global MET Inhibitor Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global MET Inhibitor Drugs Average Price by Manufacturers (2018-2023)
2.4 Global MET Inhibitor Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of MET Inhibitor Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of MET Inhibitor Drugs, Product Type & Application
2.7 MET Inhibitor Drugs Market Competitive Situation and Trends
2.7.1 MET Inhibitor Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest MET Inhibitor Drugs Players Market Share by Revenue
2.7.3 Global MET Inhibitor Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 MET Inhibitor Drugs Retrospective Market Scenario by Region
3.1 Global MET Inhibitor Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global MET Inhibitor Drugs Global MET Inhibitor Drugs Sales by Region: 2018-2029
3.2.1 Global MET Inhibitor Drugs Sales by Region: 2018-2023
3.2.2 Global MET Inhibitor Drugs Sales by Region: 2024-2029
3.3 Global MET Inhibitor Drugs Global MET Inhibitor Drugs Revenue by Region: 2018-2029
3.3.1 Global MET Inhibitor Drugs Revenue by Region: 2018-2023
3.3.2 Global MET Inhibitor Drugs Revenue by Region: 2024-2029
3.4 North America MET Inhibitor Drugs Market Facts & Figures by Country
3.4.1 North America MET Inhibitor Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America MET Inhibitor Drugs Sales by Country (2018-2029)
3.4.3 North America MET Inhibitor Drugs Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe MET Inhibitor Drugs Market Facts & Figures by Country
3.5.1 Europe MET Inhibitor Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe MET Inhibitor Drugs Sales by Country (2018-2029)
3.5.3 Europe MET Inhibitor Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific MET Inhibitor Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific MET Inhibitor Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific MET Inhibitor Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific MET Inhibitor Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America MET Inhibitor Drugs Market Facts & Figures by Country
3.7.1 Latin America MET Inhibitor Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America MET Inhibitor Drugs Sales by Country (2018-2029)
3.7.3 Latin America MET Inhibitor Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa MET Inhibitor Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa MET Inhibitor Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa MET Inhibitor Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa MET Inhibitor Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global MET Inhibitor Drugs Sales by Type (2018-2029)
4.1.1 Global MET Inhibitor Drugs Sales by Type (2018-2023)
4.1.2 Global MET Inhibitor Drugs Sales by Type (2024-2029)
4.1.3 Global MET Inhibitor Drugs Sales Market Share by Type (2018-2029)
4.2 Global MET Inhibitor Drugs Revenue by Type (2018-2029)
4.2.1 Global MET Inhibitor Drugs Revenue by Type (2018-2023)
4.2.2 Global MET Inhibitor Drugs Revenue by Type (2024-2029)
4.2.3 Global MET Inhibitor Drugs Revenue Market Share by Type (2018-2029)
4.3 Global MET Inhibitor Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global MET Inhibitor Drugs Sales by Application (2018-2029)
5.1.1 Global MET Inhibitor Drugs Sales by Application (2018-2023)
5.1.2 Global MET Inhibitor Drugs Sales by Application (2024-2029)
5.1.3 Global MET Inhibitor Drugs Sales Market Share by Application (2018-2029)
5.2 Global MET Inhibitor Drugs Revenue by Application (2018-2029)
5.2.1 Global MET Inhibitor Drugs Revenue by Application (2018-2023)
5.2.2 Global MET Inhibitor Drugs Revenue by Application (2024-2029)
5.2.3 Global MET Inhibitor Drugs Revenue Market Share by Application (2018-2029)
5.3 Global MET Inhibitor Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Abbott Laboratories
6.1.1 Abbott Laboratories Corporation Information
6.1.2 Abbott Laboratories Description and Business Overview
6.1.3 Abbott Laboratories MET Inhibitor Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Abbott Laboratories MET Inhibitor Drugs Product Portfolio
6.1.5 Abbott Laboratories Recent Developments/Updates
6.2 Johnson and Johnson
6.2.1 Johnson and Johnson Corporation Information
6.2.2 Johnson and Johnson Description and Business Overview
6.2.3 Johnson and Johnson MET Inhibitor Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Johnson and Johnson MET Inhibitor Drugs Product Portfolio
6.2.5 Johnson and Johnson Recent Developments/Updates
6.3 Novartis International AG
6.3.1 Novartis International AG Corporation Information
6.3.2 Novartis International AG Description and Business Overview
6.3.3 Novartis International AG MET Inhibitor Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Novartis International AG MET Inhibitor Drugs Product Portfolio
6.3.5 Novartis International AG Recent Developments/Updates
6.4 Eli Lilly and Company
6.4.1 Eli Lilly and Company Corporation Information
6.4.2 Eli Lilly and Company Description and Business Overview
6.4.3 Eli Lilly and Company MET Inhibitor Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Eli Lilly and Company MET Inhibitor Drugs Product Portfolio
6.4.5 Eli Lilly and Company Recent Developments/Updates
6.5 Pfizer Inc., Merck & Co.
6.5.1 Pfizer Inc., Merck & Co. Corporation Information
6.5.2 Pfizer Inc., Merck & Co. Description and Business Overview
6.5.3 Pfizer Inc., Merck & Co. MET Inhibitor Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Pfizer Inc., Merck & Co. MET Inhibitor Drugs Product Portfolio
6.5.5 Pfizer Inc., Merck & Co. Recent Developments/Updates
6.6 Takeda Pharmaceutical Company
6.6.1 Takeda Pharmaceutical Company Corporation Information
6.6.2 Takeda Pharmaceutical Company Description and Business Overview
6.6.3 Takeda Pharmaceutical Company MET Inhibitor Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Takeda Pharmaceutical Company MET Inhibitor Drugs Product Portfolio
6.6.5 Takeda Pharmaceutical Company Recent Developments/Updates
6.7 GlaxosmithKline plc
6.6.1 GlaxosmithKline plc Corporation Information
6.6.2 GlaxosmithKline plc Description and Business Overview
6.6.3 GlaxosmithKline plc MET Inhibitor Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 GlaxosmithKline plc MET Inhibitor Drugs Product Portfolio
6.7.5 GlaxosmithKline plc Recent Developments/Updates
6.8 Amgen Inc.
6.8.1 Amgen Inc. Corporation Information
6.8.2 Amgen Inc. Description and Business Overview
6.8.3 Amgen Inc. MET Inhibitor Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Amgen Inc. MET Inhibitor Drugs Product Portfolio
6.8.5 Amgen Inc. Recent Developments/Updates
6.9 Bristol Myers Squibb
6.9.1 Bristol Myers Squibb Corporation Information
6.9.2 Bristol Myers Squibb Description and Business Overview
6.9.3 Bristol Myers Squibb MET Inhibitor Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Bristol Myers Squibb MET Inhibitor Drugs Product Portfolio
6.9.5 Bristol Myers Squibb Recent Developments/Updates
6.10 Daiichi Sankyo Company, Limited
6.10.1 Daiichi Sankyo Company, Limited Corporation Information
6.10.2 Daiichi Sankyo Company, Limited Description and Business Overview
6.10.3 Daiichi Sankyo Company, Limited MET Inhibitor Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Daiichi Sankyo Company, Limited MET Inhibitor Drugs Product Portfolio
6.10.5 Daiichi Sankyo Company, Limited Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 MET Inhibitor Drugs Industry Chain Analysis
7.2 MET Inhibitor Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 MET Inhibitor Drugs Production Mode & Process
7.4 MET Inhibitor Drugs Sales and Marketing
7.4.1 MET Inhibitor Drugs Sales Channels
7.4.2 MET Inhibitor Drugs Distributors
7.5 MET Inhibitor Drugs Customers
8 MET Inhibitor Drugs Market Dynamics
8.1 MET Inhibitor Drugs Industry Trends
8.2 MET Inhibitor Drugs Market Drivers
8.3 MET Inhibitor Drugs Market Challenges
8.4 MET Inhibitor Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer